AstraZeneca's Recentin fails lung cancer trial

AstraZeneca says it will push ahead with late-stage studies of Recentin for colorectal cancer after shelving plans for a Phase III in non-small cell lung cancer due to toxicity concerns. The announcement represents a major blow to AstraZeneca, which stood to benefit from a much bigger market for lung cancer than colorectal cancer, where it could end up in a face-off with Avastin. AstraZeneca's possible earnings for Recentin in lung cancer had been estimated at a potential billion dollars. Now AstraZeneca, which has been plagued by trial failures, faces an uphill struggle in late-stage trials proving Recentin works better than Avastin.

"Although evidence of clinical activity was seen, there appeared to be an imbalance in toxicity and therefore the study was considered not to have met the pre-defined criteria for automatic continuation into Phase III," said the company about the lung cancer trial.

- check out the release
- read the report from ShareCast

Related Articles:
AstraZeneca may shake up R&D with spin-off. Report
AstraZeneca drops the axe in global R&D shakeup. Report
Big Pharma brings home the cash, slices payroll. Report
AstraZeneca lays out road map for recovery. Report
AstraZeneca touts biologics pipeline. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.